New Study Compares Obesity Medications Zepbound and Wegovy
A recent study published in the New England Journal of Medicine found that Eli Lilly's obesity drug, Zepbound (tirzepatide), resulted in nearly 50% more weight loss than Novo Nordisk's Wegovy (semaglutide) in the first head-to-head study of the two medications.
Participants who took Zepbound lost an average of 50 pounds over 72 weeks, compared to 33 pounds for those taking Wegovy. Both medications are part of a new class of medications that work by mimicking hormones in the gut and brain to regulate appetite and feelings of fullness.
Waist Circumference: is a key indicator of abdominal obesity, which is a major risk factor for various health conditions, including cardiovascular disease and type 2 diabetes. A reduction in waist circumference suggests not only weight loss but also a decrease in visceral fat, which can lead to improved health outcomes.
Primary Endpoint: The primary end point of the trial was the percent change in weight from baseline to week 72.
Sponsor: Funded by Eli Lilly suggesting that Eli Lilly was the primary or lead funder, but it does not rule out the possibility of other funders or supporters.
Full Study: READ MORE
